Bausch + Lomb Corporation (BLCO)
After hours:
| Previous close | 15.24 |
| Open | 15.24 |
| Bid | 15.48 x 800 |
| Ask | 15.66 x 900 |
| Day's range | 15.24 - 15.66 |
| 52-week range | 13.16 - 21.95 |
| Volume | |
| Avg. volume | 463,682 |
| Market cap | 5.409B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.96 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.93 |
Business WireBausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
VAUGHAN, Ontario, May 29, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the "Annual Meeting") held on May 29, 2024. The detailed results of the vote for the election of directors are set out below:
Business WireBausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
VAUGHAN, Ontario, May 28, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry’s Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024.
Business WireBausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
VAUGHAN, Ontario, May 28, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.
